CN Patent

CN1989112A — 癌症治疗方法

Assigned to SmithKline Beecham Cork Ltd · Expires 2007-06-27 · 19y expired

What this patent protects

本发明涉及通过给药哺乳动物4－喹唑啉胺(喹唑啉胺s)及包含其的药物组合物来治疗癌症的方法。具体而言，该方法涉及通过给药N－{3－氯－4－[(3－氟苯甲基)氧]苯基}－6－[5－({[2－(甲烷磺酰基)乙基]氨基}甲基)－2－呋喃基]－4－喹唑啉胺和其盐及溶剂化物来治疗由酪氨酸激酶EGFR和/或erbB2介导的癌症的方法。

USPTO Abstract

本发明涉及通过给药哺乳动物4－喹唑啉胺(喹唑啉胺s)及包含其的药物组合物来治疗癌症的方法。具体而言，该方法涉及通过给药N－{3－氯－4－[(3－氟苯甲基)氧]苯基}－6－[5－({[2－(甲烷磺酰基)乙基]氨基}甲基)－2－呋喃基]－4－喹唑啉胺和其盐及溶剂化物来治疗由酪氨酸激酶EGFR和/或erbB2介导的癌症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN1989112A
Jurisdiction
CN
Classification
—
Expires
2007-06-27
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Cork Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.